Find the right fit for you - faster
Get tailored insights about working at Insife Denmark in one quick step.
Insife Denmark Snapshot
Empowering Life Sciences with HALOPV Illuminating Innovation for Global Patient Safety
Insife is a major force in the pharmacovigilance (PV) industry. As a global PV technology company with over 130 staff, we provide game-changing solutions for the management of multi-vigilance processes, from operational to scientific. We use the best technology to create solutions for our clients, so that they can become more effective and efficient, leaving them more time to focus on their patients and their products.
Insife was founded in 2017 by CEO Martin Holm-Petersen when he realised that there were many operational systems in PV that could be vastly improved by an integrated system utilising new and advancing technology. A year later, Insife launched HALOPV, a revolutionary platform that now manages all multi-vigilance processes within its 20 modules. The success of HALOPV has meant the company has grown exponentially over the last six years.
In March 2024, it was announced that Qinecsa Solutions, specialists in technology-led end-to-end pharmacovigilance solutions, had acquired Insife. The acquisition will enable Qinecsa to leverage Insife's expertise in software development and consultancy, to enhance its existing pharmacovigilance services and accelerate further innovation in the field. Together, the companies will continue to lead the industry in advancing patient safety, drug development, and regulatory compliance through AI-driven technologies and cutting-edge solutions.
Insife was founded in 2017 by CEO Martin Holm-Petersen when he realised that there were many operational systems in PV that could be vastly improved by an integrated system utilising new and advancing technology. A year later, Insife launched HALOPV, a revolutionary platform that now manages all multi-vigilance processes within its 20 modules. The success of HALOPV has meant the company has grown exponentially over the last six years.
In March 2024, it was announced that Qinecsa Solutions, specialists in technology-led end-to-end pharmacovigilance solutions, had acquired Insife. The acquisition will enable Qinecsa to leverage Insife's expertise in software development and consultancy, to enhance its existing pharmacovigilance services and accelerate further innovation in the field. Together, the companies will continue to lead the industry in advancing patient safety, drug development, and regulatory compliance through AI-driven technologies and cutting-edge solutions.
